The majority of low-grade nomHodgkin's lymphomas (NHL) undergo clinical progression toward intermediateand high-grade lymphomas. This progression is often associated with histologic transformation from follicular to diffuse-type NHL. The pathogenetic mechanisms underlying this evolution are presently unknown. In this study, we have analyzed the role in NHL progression of relevant genetic lesions affecting proto-oncogenes and tumor suppressor genes. Sequential biopsies from 21 patients with clinical progression with (5 cases) or without (16 cases) evidence of histologic transformation were analyzed for karyotypic changes, c-myc rearrangements and deletions affecting 6q27 by Southern blot analysis, and p53 mutations by single-strand conformation polymorphism (SSCP) analysis coupled with direct sequencing of polymerase chain reaction-amplified products. No novel cytogenetic HE NATURAL HISTORY of most cases of low-grade
with poor prognostic outcome. The main features of clinical progression include enlargement of the tumor mass, appearance of novel disease sites, evolution into more advanced stages, and disease recurrence after remission. In 40% to 50% of cases, this clinical progression is associated with detectable changes in the histopathologic pattern of the tumor, typically involving transformation from a follicular to a diffuse large cell pattern (diffuse large cell lymphoma [ DLCL] .I- ' The pathogenetic basis of clinical progression in NHL is poorly understood. Various cytogenetic studies have reported the occurrence of secondary chromosomal abnormalities associated with tumor progression, although these lesions were rather heterogeneous and detectable in only a minority of cases.'-'' Investigations at the molecular level have suggested a potential role for c-myc oncogene activation based on rare observations of cases in which chromosomal translocations involving the bcl-2 oncogene, typically found in FL, coexist with translocations involving the c-myc oncogene, usually found in Burkitt's-type NHL and in a fraction of DLCL.I2.l3 However, despite these early suggestions, a recent study showed the occurrence of c-myc rearrangements in only 8% of NHL patients with histologic progression. l4 In a further attempt to identify the genetic lesion associated with disease progression in NHL, we have analyzed the role of cytogenetic and molecular lesions involving oncogenes or tumor suppressor genes in a series of 2 1 patients for whom sequential biopsies were available in the setting of clinical progression with or without histologic transformation. The results indicate that p53 mutations are associated at high frequency with histologic transformation of FL.
aberration was detected in association with progression, and all samples analyzed displayed a normal c-myc gene. Mutations of the p53 gene were detected in 4 of 5 cases displaying histologic transformation from follicular to diffuse-type NHL and in none of the 1 6 cases displaying clinical progression in the absence of histologic transformation. In 1 of these positive cases, the same mutation was also present in the pretransformation biopsy, correlating with the presence of diffuse-type areas within a predominant follicular pattern. In 1 of these cases, a deletion of 6q27 was also detected in the posttransformation biopsy along with a p53 mutation. These findings indicate that p53 mutations are associated with and may be responsible for histologic transformation of follicular lymphoma. 0 1993 by The American Society of Hematology.
MATERIALS AND METHODS
Tumor biopsies. Between January I984 and December 199 1, 78 1 consecutively ascertained specimens of histologically confirmed NHL seen at the Memorial Sloan Kettering Cancer Center were subjected to genetic analysis. Biopsy material was divided for histopathologic, cytogenetic, and immunophenotypic/immunogenotypic analyses, which were performed as previously described." Karyotypes were defined and described according to ISCN (199 Of the 78 1 specimens, 480 showed clonal chromosomal abnormalities. In 47 cases, multiple biopsies were obtained from the same patient in the setting of clinical progression of lymphoma. Of these, 21 paired samples of DNA For personal use only. on November 11, 2017 . by guest www.bloodjournal.org From tained by proteinase K digestion, phenol/chloroform extraction, and precipitation by ethanol. After digestion with appropriate restriction enzymes, 5 to I O pg of DNA was size-fractionated by electrophoresis on 0.8% agarose gel, denatured, and transferred to Duralose filters (Stratagene, La Jolla, CA) according to standard procedures." Filters were hybridized as reported elsewhere" with specific probes labeled with "P by random priming," washed in 0.2% SSC/O.5% sodium dodecyl sulfate (SDS) for 2 hours at 60°C and exposed for autoradiography at -80°C for 24 to 48 hours using intensifying screens.
DNA probes. Ig gene rearrangement analysis was performed on Hind111 and EcoRI digests by using a JH probe kindly provided by Dr S. Korsmeyer." The configuration of the c-myc locus was analyzed by hybridizing EcoRI-and HindIII-digested DNA to the MC413RC probe, representative of the third exon of the c-myc
The presence of 6q deletions was studied by loss ofconstitutional heterozygosity (LOH) analysis using the highly polymorphic cosmid clone CEB4/D6S133 (a gift of Dr G. V e r g n a~d~~) on PvuII DNA digests.
Oligonucleotideprimers. All the oligonucleotides used for polymerase chain reaction (PCR) amplification were synthesized using an Applied Biosystem synthesizer (Foster City, CA). The oligonucleotides used to amplify the sequences of p53 exons 5 through 9 have been previously rep~rted.'~ Single-strand conformation polymorphism (SSCP) analysis. SSCP analysis was performed according to an adapted version of a previously published m e t h~d .~' , '~ Briefly, PCR was performed with 100 ng of genomic DNA, 10 pmol of each primer, 2.5 pmol/L dNTPs, 1 pCi of [a-"P] dCTP, I O mmol/L Tris-HCI (pH 8.8), 50 mmol/L KCI, I mmol/L MgCl,, 0.0 1% gelatin, 0.5 U Taq polymerase (Cetus, Emeryville, CA), in a final volume of 10 pL. Thirty cycles of denaturation (94"C), annealing (63°C for reactions amplifying exons 5 , 6 , 7, and 9; and 58°C for exon 8), and extension (72°C) were performed on an automated heat-block (PerkinElmer/Cetus). The reaction mixture (2 pL) was diluted 1:25 in 0. I% SDS, 10 mmol/L EDTA and further mixed 1: 1 with a sequencing stop solution containing 20 mmol/L NaOH. Samples were heated at 95°C for 5 minutes, chilled on ice, and immediately loaded (3 pL) onto a 6% acrylamide/TBE gel containing 10% glycerol. Gels were run at 8 W for 12 to 15 hours at room temperature, fixed in 10% acetic acid, air dried, and exposed at -80°C for 6 to 72 hours using intensifying screens.
PCR was performed with 500 ng of genomic DNA, 20 pmol of each primer, 200 pmol/L dNTPs, 10 mmol/L Tris-HCI (pH 8.8), 50 mmol/L KCI, 1 mmol/L MgCI,, 0.01% gelatin, 2.5 U Taq polymerase. The number and conditions of amplification cycles were as described above. Sequencing reactions were performed as previously reported.26 Briefly, IO pmol of one of the two primers used for DNA amplification was labeled with [-y-32P] ATP (New England Nuclear, Boston, MA; specific activity, 3,000 Ci/mmol) by means of T4 polynucleotide kinase (Biolabs, Beverly. MA) and purified through a Bio-gel P4 fine column (Bio-Rad, Richmond, CA). Approximately 0.25 pmol of each fragment, previously isolated after electrophoresis in low-melting point agarose (BRL, Gaithersburg, MD), was denaturated and annealed in the presence of 2 pmol of labeled primer. Sequencing reactions were performed with reagents supplied in a T7 polymerase sequencing kit (US Biochemicals, Cleveland, OH), following the manufacturer's recommendations. Both strands were sequenced for each DNA segment analyzed.
Direct sequencing of PCR products.
RESULTS
Relevant clinical, histologic, and genetic features of the 2 1 patients selected for this study are summarized in Table   1 . The criteria for the inclusion of the sequential biopsies were ( 1) evidence of clinical progression (defined by enlargement of peripheral or visceral adenopathy, involvement of new sites, or stage progression), with or without associated histologic transformation (change in the infiltration pattern from predominantly follicular to diffuse type); and (2) evidence of identical Ig, gene rearrangements documenting the identical clonal derivation of the two biopsies (Fig 1) .
Sixteen of the 21 cases selected were representative of clinical progression in the absence of histologic transformation, whereas 5 cases displayed clinical progression associated with typical histologic transformation. The initial biopsy was taken before treatment in IO cases and after treatment in 11 cases. The median time between the sequential biopsies was 12 months. Most of the cases exhibited progression posttreatment (1 8) or off-treatment (2 cases); in I case, progression occurred while on treatment (Table 1) .
In I4 cases, including the 5 cases displaying histologic progression, a t( 14; 18) was detected. In all cases (9) in which cytogenetic analysis could be performed on both samples the t( 14;18) translocation persisted in the postprogression phase. Although there were additional cytogenetic aberrations acquired in the second biopsies, none of these aberrations were observed in more than a single sample pair.
c-myc oncogene rearrangements. Translocations involving chromosome 8 can lead to c-myc deregulation by different molecular mechanisms in distinct tumor In the most frequent t(8; 14) translocation (80% of cases), typically associated with sporadic Burkitt's lymphoma as well as a subset of diffuse large-cell NHL, c-myc is activated by truncations within its first exon, first intron, or flanking sequences. These truncations can be detected by Southern blot analysis using restriction enzymes cutting outside cmyc sequences (eg, EcoRI and HindIII).Z9 This assay showed a normal c-myc allele in all the biopsies tested (not shown), confirming previous reports indicating that c-myc oncogene activation is infrequently associated with NHL progression and transformation.14 Previous cytogenetic studies have proposed that 6q deletions may be associated with tumor progression in some Our recent molecular analysis has shown that these deletions represent a relatively frequent event in B-NHL that can be detected at the molecular level in cases displaying no microscopically visible deletion^.^' By using a highly polymorphic probe (CEB4/D6S133; heterozygosity >95%)23 mapping within the region of minimal deletion, the presence of deletions can be rapidly detected as loss of heterozygosity in Southern blot hybridization assays. This probe detected heterozygosity and thus was informative in 20 of 2 1 cases tested. However, loss of heterozygosity was detected in association with histologic transformation in only 1 case (RC 1 14 1, Fig 2) . This deletion was not detected at the cytogenetic level.
p53 inactivation in human tumors is most frequently due to point mutations in the coding sequence of exons 5 through 9 in one allele with or without loss of the other allele.31%3Z To define the occurrence of p53 Cytogenetic analysis. RC96  RC201  RC266  RC1141  RC 1039  RCll88  RC1055  RC1190  RC358  RC363  RC245  RC522  RC796  RC836  RC350  RC727  RC692  RC680  RC761  RC827  RC801  RC 1050  RC282  RC641  RClOOl  RC1112  RC472  RC683  RC362  RC567  RC859  RC1021  RC1109  RC1223  RC617  RC65 1  RC93 1  RC1243  RC511  RC954  RC482  RC500  RC492 lesions in association with NHL progression, a two-step strategy was used, as previously reported.26 p53 exons 5 through 9 were analyzed in genomic DNA of the 2 1 paired NHL samples by the PCR-SSCP technique (Fig 3A) . Fragments displaying an altered electrophoretic mobility by SSCP analysis were then reamplified in a separate reaction and analyzed by PCR-direct sequencing to confirm and characterize the nature of the mutation (representative examples are shown in Fig 3B) . Our previous control studiesz6 had shown that, under our experimental conditions, the SSCP method is sensitive at the level of at least 1% and is specific, as evaluated by the 100% concordance between the results obtained by direct sequencing versus SSCP analysis of p53 exons 5 through 9.
Deletions in chromosome band
Using this approach, p53 mutations were found in 4 of 5 cases of histologic transformation, whereas all the cases dis- Table 1 ). In 3 of the 4 cases displaying mutated p53 genes, the mutation was present only in the posttransformation biopsy. suggesting that this lesion was associated with the transformation event. In the remaining case (RC1055/1I30). the mutation was present in both biopsies. Interestingly, the first biopsy of this case was classified as having areas of diffuse growth mixed within a predominantly follicular pattern, suggesting that the p53 mutation may be associated with the dcvelopingdiffuse pattern. One ofthe cases carryinga p53 mutation in the posttransformation sample (RC I I4 I ) also carried a 6q deletion (Fig 2 and Table I ).
The characteristics of the observed p53 mutations in transformed follicular NHL aredescribed in Table 2 . In all 4 cases, the mutations were analogous for type and position to the ones observed in other types of tumors such as brain and colon can~ers.~'.~' In all cases, mutations were represented by single base pair substitutions leading to changes in the coded amino acids. The same mutation was detected in both biopsies from case RCl055/1130, confirming their identical clonal derivation. In all 4 cases. a normal p53 allele was also detected, although it could not be determined whether it was contributed by all cells (suggesting heterozygosity of the tumor cells for ~5 3 ) .
or by the high fraction of normal cells infiltrating the biopsies (tumor homozygosity or hemizygosity).
DISCUSSION
The identification of the molecular mechanisms that are associated with the clinical progression of NHL represents a critical issue with implications for the pathogenesis as well as for diagnosis and management of these malignancies. The present report confirms previous studies showing that neither frequent cytogenetic abnormalities nor c-myc activation are consistently associated with tumor progression. 8-ll.14 On the other hand, it provides the first evidence of a genetic alteration, p53 mutation. which is associated with tumor progression in cases displaying histologic transformation.
With respect to the role of recurrent chromosomal abnormalities, deletions of 6q27. I3q32, and I7p. and trisomy of chromosomes 2.3.7, and 12 have been reported in association with tumor progression in several studies, although Previous observations of two cases of NHL carrying rearranged bcl-2 and c-myc genes were taken to suggest that c-myc oncogene activation was associated with histologic transformati~n.'~,'~ This conjecture was supported by in vitro evidence of a synergistic effect of c-myc and bcl-2 in causing cell transformation and, most notably, by the observation that, in mice transgenic for bcl-2, tumor progression was frequently associated with c-myc a~t i v a t i o n . ' * ,~~,~~ In the present study, we analyzed the region of c-myc most frequently affected in sporadic NHL," and found no evidence of rearrangements in the 21 tested cases. Although rarely occumng distant 5' or 3' rearrangements cannot be ruled out, our results, together with the previous report by Yano et all4 (3 of 38), indicate that c-myc activation is an infrequent event in the clinical or histologic progression of low-grade NHL.
The main finding of our study is that p53 mutations are frequently associated with NHL that display clinical progression and histologic transformation. Although the frequency of this association is apparently high (4 of 5), the number of cases studied is limited and therefore any conclusive assessment must await confirmation based on larger panels. In support of our findings, other investigators have preliminarily reported different frequencies of association between histologic progression and p53 mutations (7 of 38 cases) or overexpression (6 of 1 l), the latter being a consequence of m~t a t i o n .~~,~~ In addition, Ichikawa et a13' have reported the association of p53 mutations with cases of advanced clinical stage and diffuse histology in NHL that may reflect histologic transformation because no p53 mutation was found in our panel of de novo diffuse large-cell lymphoma.26 Taken together, these observations identify p53 mutations as the first recurrent lesion detectable in association with histologic transformation of NHL. Given the presumed role of p53 in controlling cell proliferation and DNA replication, it is conceivable that the loss of p53 function may contribute to tumor progression directly, by providing FL cells with a high proliferative rate, and/or indirectly, by allowing the accumulation of additional genetic lesions. These lesions, such as 6q deletions, may occasionally become detectable as recurrent karyotypic abnormalities.*-'' Finally, we note that our findings may have relevant clinical implications if confirmed in larger series. p53 mutations may represent a marker for the early diagnosis of transformation that can be detected at high specificity and high sensitivity using PCR-based techniques. Indeed, the presence of a p53 mutation in one pretransformation case displaying areas of diffuse infiltration in the context of a predominantly follicular pattern suggests that the molecular lesion associated with transformation may be detectable much earlier than a canonical diagnosis of transformation is made. The validation of this approach requires the demonstration that p53 mutations are associated with early a p pearing diffuse areas and clinical studies designed to test the prognostic value of early detection of mutation.
